Endo partners up with US government on $120M infusion into the national stockpile
Endo International is expanding its manufacturing capacity at a subsidiary to help out the US national stockpile, and it’s getting funding from the government to do so.
Par Sterile Products will expand the sterile fill-finish capacity at a Rochester, MI site to up the defense efforts against future pandemics. The company will establish a new line that’s fit with the capability of processing liquid or lyophilized products that require Biosafety Level 2 containment. It will also provided inspection and packaging capacity, and the government will fund the majority of the project — $90 million of the $120 million total cost.
“Endo strives to be a force for good, and we are proud to partner with the U.S. government in its efforts to expand and accelerate domestic manufacturing in support of future pandemic preparedness,” Endo CEO Blaise Coleman said in a press release. “This collaboration underscores our longstanding history as a U.S. manufacturer of high-quality medicines.”
The agreement is part of the Defense Protection Act, which addresses vulnerabilities in the supply chain, and looks to advance manufacturing.
Endo reached an agreement with the Irish government to provide its Vasostrict vials for injections to healthcare providers in hopes of upping supply for medications critically needed to treat cases of Covid-19 earlier this month. That is also produced at the Rochester facility, and the deal addresses widespread industry drug shortages, and the supply chain issues the industry is currently experiencing.